ESLICARBAZEPINE ACETATE (eslicarbazepine acetate) by Jubilant Therapeutics is eslicarbazepine, which is considered to be responsible for therapeutic effects in humans. Approved for partial-onset seizures in patients 4 years of age, older. First approved in 2023.
Drug data last refreshed 21h ago
eslicarbazepine, which is considered to be responsible for therapeutic effects in humans. The precise mechanism(s) by which eslicarbazepine exerts anticonvulsant activity is unknown but is thought to involve inhibition of voltage-gated sodium channels.
Anti-epileptogenic Effects of Eslicarbazepine Acetate
Bioequivalence of Two Different Sources of Eslicarbazepine Acetate
Eslicarbazepine Acetate (BIA 2-093) as Monotherapy in Patients With Newly Diagnosed Partial-onset Seizures
Impact of Eslicarbazepine Acetate on Lipid Metabolism and Cardiovascular Risk Factors
A Post-marketing Study Evaluating Eslicarbazepine Acetate (ESL) as Adjunctive Treatment in Partial-Onset Seizures (Study E2093-E044-404) (EPOS)
Worked on ESLICARBAZEPINE ACETATE at Jubilant Therapeutics? Share your interview experience or compensation data (+7 days Pro)
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.